Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has commercialized the product outside of the U.S. for ~15 years.
Within the U.S., Bioventus markets 3-injection HA GELSYN-3 and 5-injection HA SUPARTZ FX. DUROLANE offers a single-injection dosing regimen.
Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has...
Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has commercialized the product outside of the U.S. for ~15 years.
Within the U.S., Bioventus markets 3-injection HA GELSYN-3 and 5-injection HA SUPARTZ FX. DUROLANE offers a single-injection dosing regimen.
Copy to clipboard 
